August 2021 Issue Table Of Contents

From The Editor

• When It’s Time

Feature Articles

• From Professor To Regenerative Medicine Company CEO

CEO Corner

• What The Sale Of Agios’ Oncology Pipeline Taught Me
• How European Biopharmas Can Benefit From Establishing A U.S. Presence

Companies To Watch

• AMO Pharma

Industry Research

• Preferred Attributes When Selecting A Phase 2/3 CRO

Inside The Industry

• After The Pandemic, Who’s Coming To The Office?
• IPO, M&A, And SPAC — 3 Life Science Execs Recount Going Public
• Why Bioscience Will Increasingly Call The Plays
• Are Oral Dose Manufacturing Projects Becoming More Complicated?
• A Q&A With A Biotech Founder/Entrepreneur
• Coming Out Of Stealth Mode: What To Know And Do
• How Pharma Executives View Future Business Travel

Industry Leader

• I’ve Learned That Hope Is At The Center Of Innovation
• Building Scientific Trust Virtually

Leadership Lessons

• How To Get The Story Learner’s Edge

Ask The Board

• What Is The Right Time For An Emerging Company To Refresh The Board To A More Commercial Orientation Prior To The Commercialization Of Its First Product?
• What Are The Characteristics Of Your Best Mentor?
• Given The Risk Profile Of An Emerging Company, What Is The Appropriate Compensation Mix Between Salary, Short-, And Long-Term (Stock) To Attract Talent?